Rituximab for refractory eosinophilic fasciitis: a case series with long-term follow-up and literature review.
Eosinophilic fasciitis
Refractory
Review
Rituximab
Treatment
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
05
03
2021
accepted:
04
05
2021
pubmed:
20
5
2021
medline:
15
12
2021
entrez:
19
5
2021
Statut:
ppublish
Résumé
RTX could be an effective and safe alternative treatment for refractory EF. Rituximab (RTX) is a successful therapeutic option for various autoimmune diseases. Our aim is to report our experience with RTX in eosinophilic fasciitis (EF) and review published data on its efficacy for the treatment of EF. We reviewed the medical charts of all patients with a diagnosis of EF treated with RTX from 2008 to 2020 in the Department of Rheumatology and Clinical Immunology in the University Hospital of Heraklion, Crete, Greece. We also reviewed the English literature for cases of EF treated with RTX. Demographics, clinical manifestations, laboratory findings, prior treatments, response to RTX, cumulative RTX dose, duration of treatment and follow-up are reported. We report three cases of EF refractory to conventional DMARDs (cDMARDs) that responded to RTX. Furthermore, literature review revealed five cases. In our case series in all patients, RTX was the first biologic. RTX could be effective in cases of (EF) refractory to standard immunosuppressive treatment.
Identifiants
pubmed: 34009397
doi: 10.1007/s00296-021-04887-3
pii: 10.1007/s00296-021-04887-3
doi:
Substances chimiques
Immunosuppressive Agents
0
Rituximab
4F4X42SYQ6
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1833-1837Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Shulman LE (1974) Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome? J Rheumatol 1(suppl 1):46–49
Baumann F, Brühlmann P, Andreisek G, Michel BA, Marincek B, Weishaupt D (2005) MRI for diagnosis and monitoring of patients with eosinophilic fasciitis. AJR Am J Roentgenol 184:169–174. https://doi.org/10.2214/ajr.184.1.01840169
doi: 10.2214/ajr.184.1.01840169
Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Moore SB (1988) Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 17:221–31
doi: 10.1016/0049-0172(88)90008-X
Scheinberg M, Hamerschlak N, Kutner JM, Ribeiro AA, Ferreira E, Goldenberg J, Kiss MH, Cjahade WH (2006) Rituximab in refractory autoimmune diseases: Brazlian experience with 29 patients. Clin Exp Rheumatol 24:65–9
De Masson A, Bouaziz JD, Peffault de Latour R, Benhamou Y, Moluçon-Chabrot C, Bay JO, Laquerrière A, Picquenot JM, Michonneau D, Leguy-Seguin V, et al (2013) Severe aplastic anemia associated with eosinophilic fasciitis. Medicine 92:69–81. https://doi.org/10.1097/md.0b013e3182899e78
doi: 10.1097/md.0b013e3182899e78
Thomson G, Johnston JL, Thomson BRJ (2015) Eosinophilic fasciitis treated with tocilizumab: demonstration of efficacy after withdrawal and re-challenge in a patient. J Rheum Dis Treat 1:1–3
doi: 10.23937/2469-5726/1510021
Chan WH, Lewis DJ, Kim EJ, Aung PP, Duvic M (2018) Generalized morphea/eosinophilic fasciitis overlap after epoxy exposure. JAAD Case Rep 4(2):175–178. https://doi.org/10.1016/j.jdcr.2017.09.006
doi: 10.1016/j.jdcr.2017.09.006
Nahhas AF, Alam M, Lim HW (2018) Rituximab as a therapeutic consideration for refractory eosinophilic fasciitis. Int J Dermatol 57(5):614–615. https://doi.org/10.1111/ijd.13940
doi: 10.1111/ijd.13940
Lebeaux D, Francès C, Barete S, Wechsler B, Dubourg O, Renoux J, Maisonobe T, Benveniste O, Gatfossé M, Bourgeois P et al (2012) Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatol (Oxf) 51(3):557–561. https://doi.org/10.1093/rheumatology/ker366
doi: 10.1093/rheumatology/ker366
Perosa F, Prete M, Racanelli V, Dammacco Fl (2010) CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med 267:260–77. https://doi.org/10.1111/j.1365-2796.2009.02207.x
doi: 10.1111/j.1365-2796.2009.02207.x
Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y on behalf of the EUSTAR Rituximab study group (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheumat Dis 74:1188–1194. https://doi.org/10.1136/annrheumdis-2013-204522
doi: 10.1136/annrheumdis-2013-204522